Small US company seeks support of analysts in its battle with Becton Dickinson
This article was originally published in Clinica
Becton Dickinson is now regarded a "prime takeover target" following its poor performance in the third quarter and predictions of worse to come, according to Michael Mullen, an analyst at Boston, Massachusetts-based SG Cowen Securities. At the same time, it is involved in a dispute with Retractable Technologies, one of the many small companies developing new safety needle technology.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.